Correction: Evaluation of endoscopic submucosal dissection as a treatment option for duodenal tumors ≥ 20 mm: a systematic review and meta-analysis by lesion size - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Assessment of Endoscopic Submucosal Dissection for Treating Duodenal Tumors ≥ 20 mm: A Systematic Review and Meta-Analysis Based on Lesion Size

  • By

  • Daisuke Minezaki

  • Yusaku Takatori

  • Motohiko Kato

  • Yasunori Sato

  • Kohei Takizawa

  • Koichi Kurahara

  • Naomi Kakushima

  • Nobutsugu Abe

  • Osamu Dohi

  • Satoru Nonaka

  • Seiichiro Fukuhara

  • Shoichi Yoshimizu

  • Shu Hoteya

  • Yasushi Yamasaki

  • Naohisa Yahagi

  • September 30, 2026

Share

  • 1

    The correction appears in volume 61, pages 523–535 (2025); DOI: 10.1007/s00535-025-02335-8.

  • 2

    Table 1's enrollment period for Inoue et al. (2014) was corrected from 2004–2019 to 1993–2011.

  • 3

    Figure 1 was published incorrectly and has been corrected in the original publication.

  • 4

    The correction includes previous incorrect versions for completeness and transparency.

  • 5

    Supplementary files 1, 2, 3, 4, and 8 have been replaced with correct versions due to errors.

Original Source(s)

Correction: Evaluation of endoscopic submucosal dissection as a treatment option for duodenal tumors ≥ 20 mm: a systematic review and meta-analysis by lesion size

  • by Daisuke Minezaki, Yusaku Takatori, Motohiko Kato, Yasunori Sato, Kohei Takizawa, Koichi Kurahara, Naomi Kakushima, Nobutsugu Abe, Osamu Dohi, Satoru Nonaka, Seiichiro Fukuhara, Shoichi Yoshimizu, Shu Hoteya, Yasushi Yamasaki, Naohisa Yahagi

  • September 30, 2026

Related Content

Error in Figure 1

  • October 5, 2026

Errors in Discussion and References

  • October 1, 2026

HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)